|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Libraries of 121 stereotactic patients were assembled on the basis of eight different parameters (a) tumor laterality, (b) whether planning target volume (PTV) dose coverage challenged by the presence of the organ at risk (OAR), (c) prescription dose and number of fractions, (d) number of PTVs, (e) tumor volume, (f) shortest distance between OAR and PTV (edge to edge distance, or EED), (g) center to center distance between OARs and PTV (CCD), and (h) lateral dimension of external contour (brain).
|
30854658 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results demonstrate for the first time that inhibition of EED modulates the tumor immune microenvironment to induce regression of colon tumors and therefore has the potential to be used in combination with immune-oncology therapy.
|
31395608 |
2019 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
MPNST frequently harbors inactivating mutations in SUZ12 or EED, resulting in PRC2 dysfunction and loss of histone H3 lysine 27 trimethylation (H3K27me3), most often seen in sporadic and radiation-associated, high-grade tumors; immunohistochemistry (IHC) for H3K27me3 is a useful diagnostic marker.
|
31107719 |
2019 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
EED biallelic alterations were detected in 2 of the other four MPNSTs, with one tumor having a homozygous EED deletion.
|
28124441 |
2017 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
In contrast, mutations of SUZ12 and EED are reported to have tumor suppressive functions.
|
27000413 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Propagation of trimethylated H3K27 regulated by polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression.
|
27578866 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Quantitative reverse transcription polymerase chain reaction techniques were used to evaluate expression levels of cancer-testis (CT) genes (NY-ESO-1, MAGE-A3, MAGE-A9, MAGE-A12, GAGE1, CT-45, SSX-1, and SSX-2), tumor suppressor (TS) genes (p16 and RASSF1A), and genes encoding epigenetic modifiers (DNMT1, DNMT3A, DNMT3B, EZH2, EED, and SUZ12), aberrantly expressed in human malignant diseases.
|
26298164 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This study identified an over expression of the epigenetic silencing complex PRC2/EED-EZH2 in breast cancer lymph node metastasis as compared to primary tumor and its positive association with tumor cell proliferation in situ.
|
23251464 |
2012 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
MiR-101 targets two subunits of PRC2 complex, enhancer of zeste homolog 2 (EZH2) and EED, and was shown to play as a tumor suppressor gene in human prostate, breast and liver cancers.
|
20444294 |
2010 |